Senolytic Therapy for Chronic Kidney Disease

Recruiting at 1 trial location

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Mayo Clinic

Must be taking: Diabetes medications

Must not be taking: Anticoagulants, Antiplatelets, Quinolones, others

Disqualifiers: Glomerulonephritis, Transplantation, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 18

Duration: 2 weeks

30 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The study goal is to assess the effect of senescent cell clearance on senescence burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC) functionality in patients with chronic kidney disease (CKD).

Who Is on the Research Team?

LaTonya J Hickson, MD

Principal Investigator

Mayo Clinic

Are You a Good Fit for This Trial?

This trial is for adults aged 40-80 with chronic kidney disease (eGFR 15-45 ml/min/1.73m2) and diabetes on medication. Excluded are those with recent substance abuse, HIV, hepatitis B/C, pregnancy, certain heart conditions or allergies to the drugs tested, among other criteria.

Inclusion Criteria

My kidney function is reduced, with an eGFR between 15-45.

I have diabetes and am on medication for it.

I am between 40 and 80 years old.

Exclusion Criteria

Your total bilirubin level is more than twice the normal limit.

I have a new cancer diagnosis that is not a non-melanoma skin cancer.

I cannot take medications by mouth.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive dasatinib and quercetin to assess the effect on senescent cell burden and mesenchymal stem cell function

2 weeks

Baseline, Day 14

Follow-up

Participants are monitored for changes in kidney function and frailty index score

12 months

Month 4, Month 12

What Are the Treatments Tested in This Trial?

Interventions

• Dasatinib
• Quercetin

Trial Overview The study tests whether Dasatinib and Quercetin can reduce aging cells in patients with chronic kidney disease to improve physical function and stem cell health. Participants will be grouped to receive either drug combination.

How Is the Trial Designed?

Group I: Group 1: Observational Active Control 1 Intervention

Observational Only

Group II: Group 2: Dasatinib & Quercetin Active Control 2 Interventions

The drugs dasatinib and quercetin will be used in this arm

Dasatinib is already approved in United States, European Union, Canada for the following indications:

Approved in United States as Sprycel for:

• Chronic myeloid leukemia (CML)
• Acute lymphoblastic leukemia (ALL)

Approved in European Union as Sprycel for:

• Chronic myeloid leukemia (CML)
• Acute lymphoblastic leukemia (ALL)

Approved in Canada as Sprycel for:

• Chronic myeloid leukemia (CML)
• Acute lymphoblastic leukemia (ALL)

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+